ARTICLE | Clinical News
Fosfomycin: Ph II/III ZEUS ongoing
January 24, 2017 2:02 AM UTC
Zavante completed treatment of 465 patients in the double-blind, international Phase II/III ZEUS trial comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days....
BCIQ Company Profiles